1. FDA(1995).Guidance for industry: Extended release oral dosage forms: Development evaluation and application of in vitro/in vivo correlations. Technical report U.S. Department of Health and Human Services FDA. Center of Drug Evaluation and Research (CDER) Rockville MD.
2. FDA(1997a).Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. Technical report U.S. Department of Health and Human Services FDA. Center of Drug Evaluation and Research (CDER) Rockville MD.
3. FDA(1997b).Guidance for industry: Immediate release solid oral dosage forms. Scale‐up and postapproval changes: Chemistry manufacturing and controls in vitro dissolution testing and in vivo bioequivalence documentation. Technical report U.S. Department of Health and Human Services FDA. Center of Drug Evaluation and Research (CDER) Rockville MD.
4. FDA(1997c).Guidance for industry: Supac‐mr: Modified release solid oral dosage forms. scale‐up and postapproval changes: Chemistry manufacturing and controls; in vitro dissolution testing and in vivo bioequivalence documentation. Technical report U.S. Department of Health and Human Services FDA. Center of Drug Evaluation and Research (CDER) Rockville MD.
5. FDA(2000).Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate‐ release solid oral dosage forms based on biopharmaceutics classification system. Technical report U.S. Department of Health and Human Services FDA. Center of Drug Evaluation and Research (CDER) Rockville MD.